Merck is a healthcare manufacturer and distributor of pharmaceuticals. The Company operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Employee Rating

3.7More
TypePublic
HQKenilworth, US
Founded1891
Size (employees)69,000 (est)
Websitemerck.com
Merck was founded in 1891 and is headquartered in Kenilworth, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Merck

Kenneth Frazier

Kenneth Frazier

Chairman of the Board, CEO
Jim Scholefield

Jim Scholefield

Chief Information and Digital Officer
Robert Davis

Robert Davis

EVP, CFO
Mirian Graddick-Weir

Mirian Graddick-Weir

EVP
Julie Gerberding

Julie Gerberding

EVP
Sanat Chattopadhyay

Sanat Chattopadhyay

President, EVP
Show more

Merck Office Locations

Merck has offices in Kenilworth, Akron, Albany, Albuquerque and in 273 other locations
Kenilworth, US (HQ)
2000 Galloping Hill Road
Boston, US
33 Avenue Louis Pasteur
Lansdale, US
770 Sumneytown Pike
North Wales, US
351 N Sumneytown Pike
Rahway, US
126 E Lincoln Ave
Sydney, AU
54-68 Ferndell Street, South Granville
Show all (278)
Report incorrect company information

Merck Financials and Metrics

Merck Revenue

Embed Graph
View revenue for all periods
Merck's revenue was reported to be $40.12 b in FY, 2017 which is a 0.8% increase from the previous period.
USD

Revenue (Q3, 2018)

10.8b

Gross profit (Q3, 2018)

7.2b

Gross profit margin (Q3, 2018), %

66.5%

Net income (Q3, 2018)

2.0b

Market capitalization (17-Jan-2019)

196.6b

Closing stock price (17-Jan-2019)

75.6

Cash (30-Sep-2018)

7.8b

EV

212.4b
Merck's current market capitalization is $196.6 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

44.0b42.2b39.5b39.8b40.1b

Revenue growth, %

(4%)(6%)1%1%

Cost of goods sold

16.0b15.2b14.4b13.9b12.8b

Gross profit

28.1b27.1b25.1b25.9b27.3b
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

9.8b10.1b9.3b9.8b10.5b9.4b9.9b10.3b10.0b10.5b10.8b

Cost of goods sold

3.6b3.6b3.4b3.0b3.1b3.3b3.2b3.4b3.6b

Gross profit

5.7b6.3b7.1b6.4b6.9b7.1b6.9b7.0b7.2b

Gross profit Margin, %

62%64%68%68%69%68%68%67%66%
Annual
USDY, 2009Y, 2010Y, 2011Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

9.3b10.9b13.5b13.5b15.6b7.4b8.5b6.5b6.1b

Accounts Receivable

7.2b6.6b6.5b7.0b6.9b

Inventories

6.2b5.6b4.7b4.9b5.1b

Current Assets

35.7b33.2b29.8b30.6b24.8b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

14.1b15.8b9.7b11.4b8.0b6.9b7.5b9.7b6.6b7.9b11.7b7.8b7.9b4.5b5.3b7.8b

Accounts Receivable

7.6b7.2b7.0b6.5b6.7b6.5b6.4b6.9b6.9b7.4b7.1b7.4b7.7b7.2b7.3b7.4b

Inventories

6.7b6.4b6.1b5.8b5.5b5.3b5.1b5.1b5.2b5.2b5.1b5.4b5.3b5.4b5.2b5.4b

Current Assets

37.8b41.2b33.6b34.7b32.9b28.3b28.6b28.8b27.9b29.4b31.5b28.2b27.9b24.1b24.1b26.8b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

4.5b11.9b4.5b3.9b2.4b

Depreciation and Amortization

6.4b5.4b4.6b

Inventories

(365.0m)79.0m805.0m206.0m(145.0m)

Accounts Payable

522.0m593.0m(37.0m)278.0m254.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

3.7b1.7b3.8b4.6b1.6b3.5b1.1b2.3b4.5b1.6b3.5b3.5b741.0m2.5b4.4b

Depreciation and Amortization

5.0b1.8b3.5b5.1b3.2b4.8b1.6b3.1b4.3b1.2b2.4b3.5b1.1b2.4b3.4b

Cash From Operating Activities

8.6b2.4b4.7b9.0b4.9b8.2b2.2b3.8b6.7b286.0m3.6b2.4b1.2b4.5b7.3b

Cash From Investing Activities

(4.3b)(3.8b)(3.9b)(7.6b)(4.1b)(4.1b)1.7b243.0m(647.0m)3.2b2.1b2.7b(197.0m)476.0m2.1b
USDY, 2018

EV/CFO

29 x

EV/FCF

37.6 x

Revenue/Employee

156.4k

Debt/Equity

0.7 x

Debt/Assets

0.3 x

Financial Leverage

2.6 x
Show all financial metrics

Merck Operating Metrics

FY, 2015FY, 2016FY, 2017May, 2018Nov, 2018

Drugs Approved by FDA

1

Phase II Trials Products

14

Phase III Trials Products

24 20 20

Products

30
Show all operating metrics

Merck Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Antelliq GroupDecember 14, 2018$2.40 b
ViralyticsFebruary 21, 2018$502 m
StayWellJuly 11, 2016
Afferent PharmaceuticalsJune 09, 2016$1.25 b
IOmet PharmaJanuary 13, 2016
cCAM BiotherapeuticsJuly 28, 2015$95 m
OncoEthixDecember 18, 2014$375 m
Cubist Pharmaceuticals, Inc.December 08, 2014$8.40 b
PreventiceSeptember 11, 2014
Peer+June 30, 2014
Show more

Merck Revenue Breakdown

Embed Graph

Merck revenue breakdown by business segment: 10.6% from Animal Health, 88.2% from Pharmaceutical and 1.1% from Other

Merck revenue breakdown by geographic segment: 43.4% from United States, 28.6% from Europe, Middle East and Africa, 10.8% from Asia Pacific, 7.8% from Japan, 5.8% from Latin America and 3.5% from Other

Report incorrect company information

Merck Online and Social Media Presence

Embed Graph
Report incorrect company information

Merck News and Updates

Merck Foundation launched their programs in partnership with Ghana's First Lady and Ministry of Health

Merck Foundation, the philanthropic arm of Merck Germany launched their programs in partnership with The First Lady of Ghana, H.E. REBECCA AKUFO-ADDO to underscore their commitment to build healthcare capacity in the country and to finalize discussions about Merck Foundation's annual conference 6th …

Animal Antimicrobials and Antibiotics Market Potential Growth, Demand and Analysis of Key Players Research Forecasts to 2026 Players Like Sanofi, Merck & Co., Inc., Zoetis, Inc., Bayer AG, Virbac, Eli Lilly Company

The rising demand for livestock products, owing to increasing population of livestock throughout the world is likely to boost growth of the animal antimicrobials and antibiotics market. Posted via Industry Today. Follow us on Twitter @IndustryToday

Acute Heart Failure (AHF) Therapeutics Market Status, Size (Value and Volume) By Manufacturers, Type, Application, And Region 2018-2026 | Top Players Pfizer Inc., Novartis AG, Cardiorentis AG, Amgen Inc., Bayer AG, Merck & Company, Inc.

The global acute heart failure therapeutics market is expected to witness significant growth due to the approval of new drugs. Posted via Industry Today. Follow us on Twitter @IndustryToday

Healthcare Supply Chain 2019 Global Market Key Players - BASF, Merck Corporation, Decartis, Bayer, Roche, Bachem, Johnson & Johnson, Sanofi-Aventis, Pfizer, AMPAC Fine Chemicals......

Healthcare Supply Chain – Global Market Growth, Opportunities, Analysis Of Top Key Players And Forecast To 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

New Report Shares Details About the Global Vaccines Market Forecast to 2025: GlaxoSmithKline, Merck, Pfizer, Sanofi, AstraZeneca

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. It typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. Posted via I…

3D Cell Culture Market Analysis and Forecast 2019-2025 with Key Players Corning, Lonza, Thermo Fisher Scientific, 3D Biotek, Synthon, Becton, Dickinson & Company, Merck & Co. Inc., Nano 3D Biosciences Inc., Sigma Aldrich Corp

3D Cell Culture Industry By Products (Scaffold-Based, Scaffold-Free, Microfluidics-Based, Magnetic Levitation & 3D Bio printing), End User(Pharmaceutical & Biotechnology Companies, Research Institutes) – Global Size Analysis and Market Forecast 2019-2025 Posted via Industry Today. Follow us …
Show more
Report incorrect company information

Merck Blogs

Merck’s KEYTRUDA® (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)

Dateline City: KENILWORTH, N.J. Results from Phase 3 KEYNOTE-181 Trial to be Presented at 2019 Gastrointestinal Cancers Symposium (ASCO GI) KENILWORTH, N.J.--(…

Merck’s KEYTRUDA® (pembrolizumab) Receives Five New Approvals in Japan, Including in Advanced Non-Small Cell Lung Cancer (NSCLC), as Adjuvant Therapy for Melanoma, and in Advanced Microsatellite Instability-High (MSI-H) Tumors

Dateline City: KENILWORTH, N.J. KEYTRUDA is the First Anti-PD-1 Approved in Japan for the First-Line Treatment of Advanced NSCLC as Both Monotherapy and in Combination with Che…

Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes

Dateline City: KENILWORTH, N.J. & SOUTH SAN FRANCISCO, Calif. KENILWORTH, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NGM Biopharmaceutical…

Merck to Participate at the 37th Annual J.P. Morgan Healthcare Conference

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, and Dr.…

FDA Approves VAXELIS™, Merck and Sanofi’s Pediatric Hexavalent Combination Vaccine

KENILWORTH, N.J. and BRIDGEWATER, N.J. – The U.S. Food and Drug Administration has approved VAXELIS™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine) for use in …

Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has extended the act…
Show more

Merck Company Life and Culture

Report incorrect company information

Merck Frequently Asked Questions

  • When was Merck founded?

    Merck was founded in 1891.

  • Who are Merck key executives?

    Merck's key executives are Kenneth Frazier, Jim Scholefield and Robert Davis.

  • How many employees does Merck have?

    Merck has 69,000 employees.

  • What is Merck revenue?

    Latest Merck annual revenue is $40.1 b.

  • What is Merck revenue per employee?

    Latest Merck revenue per employee is $581.5 k.

  • Who are Merck competitors?

    Competitors of Merck include Merck, CVS and Pfizer.

  • Where is Merck headquarters?

    Merck headquarters is located at 2000 Galloping Hill Road, Kenilworth.

  • Where are Merck offices?

    Merck has offices in Kenilworth, Akron, Albany, Albuquerque and in 273 other locations.

  • How many offices does Merck have?

    Merck has 278 offices.